Gardner, Rebecca <br/><br/>
Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy.  [electronic resource] 

 -  Blood  05 2016 
 - 2406-10 p.  digital 
<br/><br/> Publication Type: Case Reports; Journal Article 
<br/><br/><label>ISSN: </label>1528-0020 
<br/><br/><label>Standard No.: </label>10.1182/blood-2015-08-665547  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antigens, CD19--genetics<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Bone Marrow--pathology<br/>Chromosomes, Human, Pair 11--genetics<br/>Clone Cells<br/>Combined Modality Therapy<br/>Female<br/>Histone-Lysine N-Methyltransferase--genetics<br/>Humans<br/>Immunophenotyping<br/>Immunotherapy, Adoptive<br/>Infant<br/>Leukemia, Myeloid, Acute--genetics<br/>Lymphocyte Depletion<br/>Middle Aged<br/>Myeloid-Lymphoid Leukemia Protein--genetics<br/>Neoplastic Stem Cells<br/>Oncogene Proteins, Fusion--genetics<br/>Precursor B-Cell Lymphoblastic Leukemia-Lymphoma--genetics<br/>Receptors, Antigen, T-Cell--immunology<br/>Recurrence<br/>Remission Induction<br/>Salvage Therapy<br/>T-Lymphocyte Subsets--immunology<br/>Translocation, Genetic<br/>Tumor Escape